WO2001097618A2 - Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites - Google Patents

Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites Download PDF

Info

Publication number
WO2001097618A2
WO2001097618A2 PCT/EP2001/007060 EP0107060W WO0197618A2 WO 2001097618 A2 WO2001097618 A2 WO 2001097618A2 EP 0107060 W EP0107060 W EP 0107060W WO 0197618 A2 WO0197618 A2 WO 0197618A2
Authority
WO
WIPO (PCT)
Prior art keywords
amino
methyl
carbonyl
pyrrol
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/007060
Other languages
French (fr)
Other versions
WO2001097618A3 (en
Inventor
Maria Cristina Rosa Geroni
Paolo Cozzi
Italo Beria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia Italia SpA
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200300059A priority Critical patent/EA006709B1/en
Priority to KR1020027017409A priority patent/KR100861668B1/en
Priority to HU0301334A priority patent/HUP0301334A3/en
Priority to MXPA02012165A priority patent/MXPA02012165A/en
Priority to US10/297,620 priority patent/US7642229B2/en
Priority to PL363696A priority patent/PL200504B1/en
Priority to IL15317801A priority patent/IL153178A0/en
Priority to DE60143681T priority patent/DE60143681D1/en
Priority to AU2001267553A priority patent/AU2001267553B2/en
Priority to EP01945297A priority patent/EP1299110B1/en
Priority to JP2002503104A priority patent/JP2003535874A/en
Priority to BR0111814-5A priority patent/BR0111814A/en
Priority to EEP200200688A priority patent/EE05359B1/en
Priority to AU6755301A priority patent/AU6755301A/en
Priority to CA002412054A priority patent/CA2412054A1/en
Priority to DE60136706T priority patent/DE60136706D1/en
Priority to HK03106774.6A priority patent/HK1054506B/en
Priority to SK1829-2002A priority patent/SK287398B6/en
Priority to NZ523001A priority patent/NZ523001A/en
Application filed by Pharmacia Italia SpA, Pharmacia and Upjohn SpA filed Critical Pharmacia Italia SpA
Publication of WO2001097618A2 publication Critical patent/WO2001097618A2/en
Publication of WO2001097618A3 publication Critical patent/WO2001097618A3/en
Priority to IL153178A priority patent/IL153178A/en
Priority to NO20026076A priority patent/NO329967B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to the field of cancer treatment and provides an antitumor composition
  • an antitumor composition comprising a substituted acryloyl distamycin derivative, more particularly an ⁇ -bromo- or ⁇ -chloro-acryloyl distamycin derivative, an antimicrotubule agent and/or an antimetabolite, having a synergistic antineoplastic effect.
  • Distamycin A and analogues thereof are known in the art as cytotoxic agents useful in antitumor therapy.
  • Distamycin A is an antibiotic substance with antiviral and antiprotozoal activity, having a polypyrrole framework [Nature 203: 1064 (1964); J. Med. Chem. 32: 774-778 (1989)].
  • the international patent applications WO 90/11277, WO 98/04524, WO 98/21202, WO 99/50265, WO 99/50266 and WO 01/40181 (claiming priority from British patent application No.
  • the present invention provides, in a first aspect, a pharmaceutical composition for use in antineoplastic therapy in mammals, including humans, comprising a pharmaceutically acceptable carrier or excipient; an acryloyl distamycin derivative of formula (I):
  • Ri is a bromine or chlorine atom
  • R 2 is a distamycin or distamycin-like framework; or a pharmaceutically acceptable salt thereof; and an antimicrotubule agent and/or an antimetabolite.
  • the present invention includes, within its scope, the pharmaceutical compositions comprising any of the possible isomers covered by the compounds of formula (I), both considered separately or in admixture, as well as the metabolites and the pharmaceutically acceptable bio-precursors (otherwise known as pro-drugs) of the compounds of formula (I) .
  • distamycin or distamycin-like framework R 2 we intend any moiety structurally closely related to distamycin itself, for instance by optionally replacing the ending amidino moiety of distamycin and/or its polypyrrole framework, or part of it.
  • Antimicrotubule agents and antimetabolites are widely known in the art as antitumor agents; see, for a general reference, Cancer, Principles and Practice of Oncology, Lippincort-Raven Ed. (1997), 432-452 and 467-483
  • the antimicrotubule agents are, for instance, taxanes, e.g. paclitaxel or docetaxel; vinca alkaloids, e.g. vincristine, vinblastine, vindesine, vinorelbine; and estramustine, optionally encapsulated within liposomes.
  • Preferred antimetabolites are, for instance, antifolates, e.g. metotrexate, trimetrexate, tomudex; 5-fluoropyrimidines, e.g. 5-FU, floxuridine, ftorafur and capecitabine; cytidine analogs, e.g. cytarabine, azacitidine and gemcitabine.
  • antimicrotubule agents are paclitaxel and estramustine whereas preferred antimetabolites are 5-fluorouracil or gemcitabine.
  • X and Y are, the same or different and independently for each heterocycUc ring, a nitrogen atom or a CH group;
  • G is phenylene, a 5 or 6 membered saturated or unsaturated heterocycUc ring with from 1 to 3 heteroatoms selected among N, O or S, or it is a group of formula (J_H) below:
  • Q is a nitrogen atom or a CH group and W is an oxygen or sulfur atom or it is a group NR wherein R 3 is hydrogen or Cj-C 4 alkyl; B is selected from the group consisting of
  • R is cyano, amino, hydroxy or C ⁇ -C 4 alkoxy
  • R 5 , R 6 and R 7 are hydrogen or -C 4 alkyl.
  • C ⁇ -C alkyl or alkoxy group we intend a straight or branched group selected from methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy. ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy.
  • compositions of the invention comprising the above acryloyl distamycin derivative of formula (I) wherein Ri is bromine or chlorine; R 2 is the above group of formula (TJ) wherem r is 0, m is 0 or 1, n is 4 and B has the above reported meanings. Still more preferred, within this class, are the pharmaceutical compositions comprising the compounds of formula (I) wherein Ri is bromine or chlorine; R 2 is the above group of formula (II) wherein r is 0, m is 0 or 1, n is 4, X and Y are both CH groups and B is selected from:
  • R 4 is cyano or hydroxy and R 5 , Re and R 7 , the same or different, are hydrogen or C ⁇ -C alkyl.
  • Pharmaceutically acceptable salts of the compounds of formula (I) are those with pharmaceutically acceptable inorganic or organic acids such as, for instance, hydrochloric, hydrobromic, sulfuric, nitric, acetic, propionic, succinic, malonic, citric, tartaric, methanesulfonic, p-toluenesulfonic acid and the like.
  • compositions object of the invention optionally in the form of pharmaceutically acceptable salts, preferably with hydrochloric acid, are:
  • the present invention further provides a product comprising an acryloyl distamycin derivative of formula (I), as defined above, an antimicrotubule agent and/or an antimetabolite, as a combined preparation for simultaneous, separate or sequential use in antitumor therapy.
  • a product comprising N-(5- ⁇ [(5- ⁇ [(5- ⁇ [(5- ⁇ [(2- [amino(imino)methyl]amino ⁇ ethyl)amino]carbonyl ⁇ -l-methyl-lH-pyrrol-3- yl)amino] carbonyl ⁇ - 1 -methyl- 1 H-pyrrol-3 -yl)amino] carbonyl ⁇ - 1 -methyl- lH-pyrrol-3 - yl)-4-[(2-bromoacryloyl)amino]-l-methyl-lH-pyrrole-2-carboxamide hydrochloride (internal code PNU 166196) and gemcitabine, as a combined preparation for simultaneous, separate or sequential use in antitumor therapy.
  • a further aspect of the present invention is to provide a method of treating a mammal, including humans, suffering from a neoplastic disease state, which method comprises administering to said mammal the above acryloyl distamycin derivative of formula (I), an antimicrotubule agent and/or an antimetabolite, in amounts effective to produce a synergistic antineoplastic effect.
  • the present invention also provides a method for lowering the side effects caused by antineoplastic therapy with an antineoplastic agent in a mammal in need thereof, including humans, the method comprising administering to said mammal a combined preparation comprising an acryloyl distamycin derivative of formula (I), an antimicrotubule agent and/or an antimetabolite, in amounts effective to produce a synergistic antineoplastic effect.
  • antineoplastic effect it is meant the inhibition of the growth tumor, preferably the complete regression of the tumor, by administering an effective amount of the combination comprising an acryloyl distamycin derivative of formula (I), an antimicrotubule agent and/or an antimetabolite to mammals, including humans.
  • admimstered or “administering”, as used herein, it is meant parenteral and/or oral administration; the term “parenteral” means intravenous, subcutaneous and intramuscular administration.
  • the acryloyl distamycin derivative may be admimstered simultaneously with the antimicrotubule agent or with the antimetabolite.
  • the two drugs may be administered sequentially in either order.
  • the drugs are preferably administered sequentially, in any order.
  • the actual preferred method and order of administration will vary according to, inter alias, the particular formulation of the acryloyl distamycin of formula (I) being used, the particular formulation of the antimicrotubule agent and/or the antimetabolite being used, the particular tumor model being treated as well as the particular host being treated.
  • the course of therapy generally employed comprises doses varying from about 0.05 to about 100 mg/m 2 of body surface area and, more preferably, from about 0J to about 50 mg/m 2 of body surface area.
  • the course of therapy generally employed comprises doses varying from about 1 to about 1000 mg/m 2 of body surface area and, more preferably, from about 10 to about 500 mg/m 2 of body surface area.
  • the course of therapy generally employed comprises doses varying from about 0J to about 1000 mg/m 2 of body surface area and, more preferably, from about 0.5 to about 100 mg/m of body surface area.
  • the course of therapy generally employed comprises doses varying from about 0J to about 10 g/m 2 of body surface area and, more preferably, from about 1 to about 5 g/m 2 of body surface area.
  • the antineoplastic therapy of the present invention is particularly suitable for treating breast, ovary, lung, colon, kidney, stomach, pancreas, liver, melanoma, leukemia and brain tumors in mammals, including humans.
  • the present invention is directed to a composition
  • a composition comprising an effective amount of an acryloyl distamycin derivative of formula (I), as defined above, an antimicrotubule agent and/or an antimetabolite, in the preparation of a medicament for use in the prevention or treatment of metastasis or in the treatment of tumors by inhibition of angiogenesis.
  • the effect of an acryloyl distamycin derivative of formula (I) with an antimicrotubule agent and/or an antimetabolite is significantly increased without a parallel increase of toxicity.
  • the combined therapy of the present invention enhances the antitumoral effects of the acryloyl distamycin derivative and of the other drug, being either an antimicrotubule, an antimetabolite or a combination thereof and, hence, provides the most effective and least toxic treatment for tumors.
  • Table 1 shows the antileukemic activity on disseminated L1210 murine leukemia obtained by combining N-(5- ⁇ [(5- ⁇ [(5- ⁇ [(2-)
  • Table 1 Antileukemic activity against disseminated L1210 1 murine leukemia of an acryloyl distamycin derivative (I) in combination with gemcitabine.
  • L1210 leukemia cells (10 5 /mouse) are injected iv on day 0.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention provides the combined use of acryloyl distamycin derivatives, in particular α-bromo- and -α-chloro-acryloyl distamycin derivatives of formula (I), as set forth in the specification, antimicrotubule agents and/or an antimetabolites. Also provided is the use of the said combination in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis.

Description

COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES, TAXANES AND/OR ANTIMETABOLITES
The present invention relates to the field of cancer treatment and provides an antitumor composition comprising a substituted acryloyl distamycin derivative, more particularly an α-bromo- or α-chloro-acryloyl distamycin derivative, an antimicrotubule agent and/or an antimetabolite, having a synergistic antineoplastic effect.
Distamycin A and analogues thereof, hereinafter referred to as distamycin and distamycin-like derivatives, are known in the art as cytotoxic agents useful in antitumor therapy.
Distamycin A is an antibiotic substance with antiviral and antiprotozoal activity, having a polypyrrole framework [Nature 203: 1064 (1964); J. Med. Chem. 32: 774-778 (1989)]. The international patent applications WO 90/11277, WO 98/04524, WO 98/21202, WO 99/50265, WO 99/50266 and WO 01/40181 (claiming priority from British patent application No. 9928703.9), all in the name of the applicant itself and herewith incorporated by reference, disclose acryloyl distamycin derivatives wherein the amidino moiety of distamycin is optionally replaced by nitrogen-containing ending groups such as, for instance, cyanamidino, N-methylamidino, guanidino, carbamoyl, amidoxime, cyano and the like, and/or wherein the polypyrrole framework of distamycin, or part of it, is replaced by varying carbocyclic or heterocyclic moieties.
The present invention provides, in a first aspect, a pharmaceutical composition for use in antineoplastic therapy in mammals, including humans, comprising a pharmaceutically acceptable carrier or excipient; an acryloyl distamycin derivative of formula (I):
Figure imgf000002_0001
wherein: Ri is a bromine or chlorine atom;
R2 is a distamycin or distamycin-like framework; or a pharmaceutically acceptable salt thereof; and an antimicrotubule agent and/or an antimetabolite.
The present invention includes, within its scope, the pharmaceutical compositions comprising any of the possible isomers covered by the compounds of formula (I), both considered separately or in admixture, as well as the metabolites and the pharmaceutically acceptable bio-precursors (otherwise known as pro-drugs) of the compounds of formula (I) .
In the present description, unless otherwise specified, with the term distamycin or distamycin-like framework R2 we intend any moiety structurally closely related to distamycin itself, for instance by optionally replacing the ending amidino moiety of distamycin and/or its polypyrrole framework, or part of it.
Antimicrotubule agents and antimetabolites are widely known in the art as antitumor agents; see, for a general reference, Cancer, Principles and Practice of Oncology, Lippincort-Raven Ed. (1997), 432-452 and 467-483
According to a preferred embodiment of the invention, herewith provided are the above pharmaceutical compositions wherein the antimicrotubule agents are, for instance, taxanes, e.g. paclitaxel or docetaxel; vinca alkaloids, e.g. vincristine, vinblastine, vindesine, vinorelbine; and estramustine, optionally encapsulated within liposomes. Preferred antimetabolites are, for instance, antifolates, e.g. metotrexate, trimetrexate, tomudex; 5-fluoropyrimidines, e.g. 5-FU, floxuridine, ftorafur and capecitabine; cytidine analogs, e.g. cytarabine, azacitidine and gemcitabine.
Particularly preferred antimicrotubule agents are paclitaxel and estramustine whereas preferred antimetabolites are 5-fluorouracil or gemcitabine.
According to another preferred embodiment of the invention, herewith provided are the above pharmaceutical compositions wherein, within the acryloyl distamycin derivative of formula (I), R has the above reported meanings and R is a group of formula (H) below:
Figure imgf000004_0001
wherein m is an integer from 0 to 2; n is an integer from 2 to 5; r is O or 1;
X and Y are, the same or different and independently for each heterocycUc ring, a nitrogen atom or a CH group;
G is phenylene, a 5 or 6 membered saturated or unsaturated heterocycUc ring with from 1 to 3 heteroatoms selected among N, O or S, or it is a group of formula (J_H) below:
Figure imgf000004_0002
wherein Q is a nitrogen atom or a CH group and W is an oxygen or sulfur atom or it is a group NR wherein R3 is hydrogen or Cj-C4 alkyl; B is selected from the group consisting of
Figure imgf000004_0003
CN NR5R6 — CONR5R6 — NHCONR5R6
wherein R is cyano, amino, hydroxy or Cι-C4 alkoxy; R5, R6 and R7, the same or different, are hydrogen or -C4 alkyl. hi the present description, unless otherwise specified, with the term Cι-C alkyl or alkoxy group we intend a straight or branched group selected from methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy. ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy.
Even more preferred are the pharmaceutical compositions of the invention comprising the above acryloyl distamycin derivative of formula (I) wherein Ri is bromine or chlorine; R2 is the above group of formula (TJ) wherem r is 0, m is 0 or 1, n is 4 and B has the above reported meanings. Still more preferred, within this class, are the pharmaceutical compositions comprising the compounds of formula (I) wherein Ri is bromine or chlorine; R2 is the above group of formula (II) wherein r is 0, m is 0 or 1, n is 4, X and Y are both CH groups and B is selected from:
Figure imgf000005_0001
— CN . — CONR5R6 — NHCONR5R6
' ; wherein R4 is cyano or hydroxy and R5, Re and R7, the same or different, are hydrogen or Cι-C alkyl.
Pharmaceutically acceptable salts of the compounds of formula (I) are those with pharmaceutically acceptable inorganic or organic acids such as, for instance, hydrochloric, hydrobromic, sulfuric, nitric, acetic, propionic, succinic, malonic, citric, tartaric, methanesulfonic, p-toluenesulfonic acid and the like.
Examples of preferred acryloyl distamycin derivatives of formula (I), within the compositions object of the invention, optionally in the form of pharmaceutically acceptable salts, preferably with hydrochloric acid, are:
1. N-(5- {[(5- {[(5- {[(2- {[amino(imino)methyl]amino} ethyl)amino]carbonyl} -1 - methyl- 1 H-pyrrol-3 -yl)amino] carbonyl} - 1 -methyl- 1 H-pyrrol-3 - yl)amino jcarbonyl} - 1 -methyl- lH-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]- 1 - methyl-lH-pyrrole-2-carboxamide hydrochloride;
2. N-(5-{[(5-{[(5-{[(2-{[amino(imino)methyl]ammo}propyl)amino]carbonyl}-l- methyl- 1 H-pyrrol-3 -yl)amino] carbonyl} - 1 -methyl- 1 H-pyrrol-3 - yl)amino] carbonyl} - 1 -methyl- 1 H-pyrrol-3 -yl)-4- [(2-bromoacryloyl)amino]- 1 - methyl-lH-pyrrole-2-carboxamide hydrochloride;
3. N-(5-{[(5-{[(5-{[(3-amino-3-iminopropyl)amino]carbonyl}-l-methyl-lH-pyrrol-3- yl)amino]carbonyl} - 1 -methyl- lH-pyrrol-3-yl)amino]carbonyl} - 1 -methyl- 1 H- pyrrol-3 -yl)-4- [(2-bromoacryloyl)amino] - 1 -methyl- 1 H-pyrrole-2-carboxamide hydrochloride;
4. N-(5- { [(5 - { [(5 - { [(3 -amino-3 -iminopropyl)amino] carbonyl} - 1 -methyl- 1 H-pyrrol-3 - yl)amino] carbonyl} - 1 -methyl- 1 H-pyrrol-3 -yl)amino] carbonyl} - 1 -methyl- 1 H- pyrrol-3 -yl)-4- [(2-bromoacryloyl)amino] - 1 -methyl- 1 H-imidazole-2-carboxamide hydrochloride; 5. N-(5-{[(5-{[(5-{[(3 -amino-3 -iminopropyl)amino] carbonyl} - 1 -methyl- 1 H-pyrrol-3 - yl)amino] carbonyl} - 1 -methyl- 1 H-pyrrol-3 -yl)amino] carbonyl} - 1 -methyl- 1 H- pyrrol-3-yl)-3-[(2-bromoacryloyl)amino]-l-methyl-lH-pyrazole-5-carboxamide hydrochloride;
6. N-(5-{[(5-{[(5-{[(3-amino-3-oxopropyl)amino]carbonyl}-l-methyl-lH-pyrrol-3- yl)amino] carbonyl} - 1 -methyl- 1 H-pyrrol-3-yl)amino] carbonyl} - 1 -methyl- 1 H- pyrrol-3-yl)-3-[(2-bromoacryloyl)amino]-l-methyl-lH-pyrazole-5-carboxamide;
7. N-(5-{[(5-{[(5-{[(2-{ [amino(imino)methyl] amino } ethyl)amino] carbonyl} - 1 - methyl- 1 H-pyrrol-3 -yl)amino] carbonyl} - 1 -methyl- 1 H-pyrrol-3 - yl)amino]carbonyl}-l-methyl-lH-pyrrol-3-yl)-4-[(2-chloroacryloyl)amino]-l- methyl- 1 H-pyrrole-2-carboxamide hydrochloride;
8. N-(5- { [(5- { [(3 - {[amino(imino)methyl] amino}propyl)amino] carbonyl} - 1 -methyl- 1 H-pyrrol-3 -yl)amino] carbonyl} - 1 -methyl- 1 H-pyrrol-3 -yl)-4- [(2- bromoacryloyl)amino] - 1 -methyl- 1 H-p yrrole-2-carboxamide hydrochloride;
9. N-(5-{[(5-{[(3-ammo-3-iminopropyl)amino]carbonyl}-l-methyl-lH-pyrrol-3- yl)amino]carbonyl}-l-methyl-lH-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-l- methyl-lH-pyrrole-2-carboxamide hydrochloride; and 10. N-{5-[({5-[({5-[({3-[(aminocarbonyl)amino]propyl}amino)carbonyl]-l-ιτιethyl- 1 H-pyrrol-3 -yl } amino)carbonyl] - 1 -methyl- 1 H-pyrrol-3 -yl} amino)carbonyl] - 1 - methyl- 1 H-pyrrol-3 -yl} -4- [(2-bromoacryloyl)amino] - 1 -methyl- 1 H-pyrrole-2- carboxamide.
The above compounds of formula (I), either specifically identified as such or by means of the general formula, are known or easily prepared according to known methods as reported, for instance, in the aforementioned international patent applications WO 90/11277, WO 98/04524, WO 98/21202, WO 99/50265 and WO 99/50266 and WO 01/40181.
The present invention further provides a product comprising an acryloyl distamycin derivative of formula (I), as defined above, an antimicrotubule agent and/or an antimetabolite, as a combined preparation for simultaneous, separate or sequential use in antitumor therapy.
Particularly preferred, in this respect, is a product comprising N-(5-{[(5-{[(5-{[(2- [amino(imino)methyl]amino}ethyl)amino]carbonyl}-l-methyl-lH-pyrrol-3- yl)amino] carbonyl} - 1 -methyl- 1 H-pyrrol-3 -yl)amino] carbonyl} - 1 -methyl- lH-pyrrol-3 - yl)-4-[(2-bromoacryloyl)amino]-l-methyl-lH-pyrrole-2-carboxamide hydrochloride (internal code PNU 166196) and gemcitabine, as a combined preparation for simultaneous, separate or sequential use in antitumor therapy.
A further aspect of the present invention is to provide a method of treating a mammal, including humans, suffering from a neoplastic disease state, which method comprises administering to said mammal the above acryloyl distamycin derivative of formula (I), an antimicrotubule agent and/or an antimetabolite, in amounts effective to produce a synergistic antineoplastic effect.
The present invention also provides a method for lowering the side effects caused by antineoplastic therapy with an antineoplastic agent in a mammal in need thereof, including humans, the method comprising administering to said mammal a combined preparation comprising an acryloyl distamycin derivative of formula (I), an antimicrotubule agent and/or an antimetabolite, in amounts effective to produce a synergistic antineoplastic effect. By the term "synergistic antineoplastic effect", as used herein, it is meant the inhibition of the growth tumor, preferably the complete regression of the tumor, by administering an effective amount of the combination comprising an acryloyl distamycin derivative of formula (I), an antimicrotubule agent and/or an antimetabolite to mammals, including humans. By the term "admimstered " or "administering", as used herein, it is meant parenteral and/or oral administration; the term "parenteral" means intravenous, subcutaneous and intramuscular administration.
In the method of the present invention, the acryloyl distamycin derivative may be admimstered simultaneously with the antimicrotubule agent or with the antimetabolite.
Alternatively, the two drugs may be administered sequentially in either order.
When the acryloyl distamycin derivative is administered with both the antimicrotubule agent and the antimetabolite, according to an embodiment of the invention, the drugs are preferably administered sequentially, in any order. In this respect, it will be appreciated that the actual preferred method and order of administration will vary according to, inter alias, the particular formulation of the acryloyl distamycin of formula (I) being used, the particular formulation of the antimicrotubule agent and/or the antimetabolite being used, the particular tumor model being treated as well as the particular host being treated. To administer the acryloyl distamycin derivative of formula (I), according to the method of the invention, the course of therapy generally employed comprises doses varying from about 0.05 to about 100 mg/m2 of body surface area and, more preferably, from about 0J to about 50 mg/m2 of body surface area.
For the admimstration of the taxanes, according to the method of the invention, the course of therapy generally employed comprises doses varying from about 1 to about 1000 mg/m2 of body surface area and, more preferably, from about 10 to about 500 mg/m2 of body surface area.
For the administration of the vinca alkaloids, according to the method of the invention, the course of therapy generally employed comprises doses varying from about 0J to about 1000 mg/m2 of body surface area and, more preferably, from about 0.5 to about 100 mg/m of body surface area.
For the administration of the antimetabolite according to the invention, the course of therapy generally employed comprises doses varying from about 0J to about 10 g/m2 of body surface area and, more preferably, from about 1 to about 5 g/m2 of body surface area.
The antineoplastic therapy of the present invention is particularly suitable for treating breast, ovary, lung, colon, kidney, stomach, pancreas, liver, melanoma, leukemia and brain tumors in mammals, including humans.
In a further aspect, the present invention is directed to a composition comprising an effective amount of an acryloyl distamycin derivative of formula (I), as defined above, an antimicrotubule agent and/or an antimetabolite, in the preparation of a medicament for use in the prevention or treatment of metastasis or in the treatment of tumors by inhibition of angiogenesis.
As stated above, the effect of an acryloyl distamycin derivative of formula (I) with an antimicrotubule agent and/or an antimetabolite, is significantly increased without a parallel increase of toxicity. In other words, the combined therapy of the present invention enhances the antitumoral effects of the acryloyl distamycin derivative and of the other drug, being either an antimicrotubule, an antimetabolite or a combination thereof and, hence, provides the most effective and least toxic treatment for tumors.
The superadditive effects of the combined preparations of the invention are shown, for instance, by the following in vivo antitumor activity data which are intended to illustrate the present invention without posing any limitation to it. Table 1 shows the antileukemic activity on disseminated L1210 murine leukemia obtained by combining N-(5-{[(5-{[(5-{[(2-
{ [amino(imino)methyl] amino } ethyl)amino] carbonyl } - 1 -methyl- 1 H-pyrrol-3 - yl)amino]carbonyl} - 1 -methyl- lH-pyrrol-3-yl)amino]carbonyl} - 1 -methyl- lH-pyrrol-3- yl)-4- [(2-bromoacryloyl)amino] - 1 -methyl- 1 H-pyrrole-2-carboxamide hydrochloride, as a representative compound of formula (I) - internal code PNU 166196, with gemcitabine.
At the dose of 15 mg/kg of gemcitabine alone (day +1 after tumor injection, 2 h after PNU 166196 administration) and at the dose of 0J mg/kg of PNU 166196 alone (days +1,6) were associated, without toxicity, ILS% values of 50 and 58, respectively. Combining gemcitabine and PNU 166196 at the same doses with the same schedule, an increase of activity with T_LS% values of 127 were observed, thus indicating a synergistic effect.
Table 1: Antileukemic activity against disseminated L12101 murine leukemia of an acryloyl distamycin derivative (I) in combination with gemcitabine.
Figure imgf000010_0001
1) L1210 leukemia cells (105/mouse) are injected iv on day 0.
2) Treatment is given starting on day 1 after tumor transplantation (day 0).
3) Increase in life span: [(median survival time of treated mice/median survival time of controls)x 100]- 100
4) Number of toxic deaths/number of mice.
(*) treatment 2 h after PNU 166196 administration.

Claims

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and, as active ingredient, an acryloyl distamycin derivative of formula (I):
Figure imgf000011_0001
wherein:
Ri is a bromine or chlorine atom;
R is a distamycin or distamycin-like framework; or a pharmaceutically acceptable salt thereof; and an antimicrotubule agent and/or an antimetabolite.
2. A pharmaceutical composition according to claim 1 wherein the antimicrotubule agent is selected from taxanes, including paclitaxel and docetaxel; vinca alkaloids, including vmcristine, vinblastine, vindesine, vinorelbine; and estramustine, optionally encapsulated within liposomes.
3. A pharmaceutical composition according to claim 2 wherein the antimicrotubule agent is paclitaxel or estramustine.
4. A pharmaceutical composition according to claim 1 wherein the antimetabolite is selected from antifolates, including methotrexate, tomudex and trimetrexate; 5- fluoropyrimidine derivatives, including 5-fluorouracil, floxuridine, ftorafur and capecitabine; and cytidine analogs, including cytarabine, azacitidine and gemcitabine.
5. A pharmaceutical composition according to claim 4 wherein the antimetabolite is selected from 5-fluorouracil or gemcitabine.
6. A pharmaceutical composition according to claim 1 comprising an acryloyl distamycin derivative of formula (I)
Figure imgf000012_0001
wherein:
Ri is a bromine or chlorine atom;
R2 is a group of formula (11)
Figure imgf000012_0002
wherein m is an integer from 0 to 2; n is an integer from 2 to 5; r is O or 1;
X and Y are, the same or different and independently for each heterocycUc ring, a nitrogen atom or a CH group;
G is phenylene, a 5 or 6 membered saturated or unsaturated heterocycUc ring with from 1 to 3 heteroatoms selected among N, O or S, or it is a group of formula (ID) below:
Figure imgf000012_0003
wherein Q is a nitrogen atom or a CH group and W is an oxygen or sulfur atom or it is a group NR3 wherein R3 is hydrogen or Cι-C alkyl; B is selected from the group consisting of
Figure imgf000013_0001
— CN . -NR5R6 . - - CONR5R6 — NHCONR5R6
wherein R is cyano, amino, hydroxy or Cι-C4 alkoxy; R5, R6 and R7, the same or different, are hydrogen or Cι-C alkyl.
7. A pharmaceutical composition according to claim 6 comprising an acryloyl distamycin derivative of formula (I) wherein Ri, R2 and B are as defined in claim 6, r is 0, m is 0 or 1 and n is 4.
8. A pharmaceutical composition according to claim 7 comprising an acryloyl distamycin derivative of formula (I) wherein Ri and R are as defined in claim 6, r is 0, m is 0 or 1, n is 4, X and Y are both CH groups and B is selected from:
Figure imgf000013_0002
— CN . — CONR5R6 — NHCONR5R6 i wherein R-j is cyano or hydroxy and R5, R6 and R7, the same or different, are hydrogen or Cι-C4 alkyl.
9. A pharmaceutical composition according to claim 1 comprising an acryloyl distamycin derivative, optionally in the form of a pharmaceutically acceptable salt, selected from the group consisting of:
1. N-(5- { [(5- { [(5- { [(2- { [amino(imino)methyl] amino} ethyl)amino] carbonyl} - 1 - methyl-lH-pyrrol-3-yl)amino]carbonyl}-l-methyl-lH-pyrrol-3- yl)amino]carbonyl}-l-methyl-lH-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-l- methyl- 1 H-pyrrole-2-carboxamide hydrochloride;
2. N-(5- {[(5- {[(5- {[(2- {[amino(imino)methyl]amino}propyl)amino]carbonyl} -1 - methyl-lH-pyrrol-3-yl)amino]carbonyl}-l-methyl-lH-pyrrol-3- yl)amino]carbonyl}-l-methyl-lH-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-l- methyl- 1 H-pyrrole-2-carboxamide hydrochloride;
3. N-(5-{[(5-{[(5-{[(3-ammo-3-iminopropyl)amino]carbonyl}-l-methyl-lH-pyrrol-3- yl)amino] carbonyl} - 1 -methyl- 1 H-pyrrol-3 -yl)amino] carbonyl} - 1 -methyl- 1 H- pyrrol-3 -yl)-4- [(2-bromoacryloyl)amino] - 1 -methyl- 1 H-pyrrole-2-carboxamide hydrochloride;
4. N-(5-{[(5-{[(5-{[(3-amino-3-iminopropyl)amino]carbonyl}-l-methyl-lH-pyrrol-3- yl)amino] carbonyl} - 1 -methyl- 1 H-pyrrol-3 -yl)amino] carbonyl} - 1 -methyl- 1H- pyι ol-3-yl)-4-[(2-bromoacιyloyl)amino]-l-memyl-lH-imidazole-2-carboxamide hydrochloride; 5. N-(5-{[(5-{[(5-{[(3-amino-3-iminopropyl)amino]carbonyl}-l-methyl-lH-pyrrol-3- yl)amino] carbonyl} -1 -methyl- 1 H-pyrrol-3 -yl)amino] carbonyl} - 1 -methyl- 1 H- pyrrol-3-yl)-3-[(2-bromoacryloyl)amino]-l-methyl-lH-pyrazole-5-carboxamide hydrochloride;
6. N-(5-{[(5-{[(5-{[(3-amino-3-oxopropyl)amino]carbonyl}-l-methyl-lH-pyπOl-3- yl)amino]carbόnyl} - 1 -methyl- 1 H-pyrrol-3-yl)amino]carbonyl} - 1 -methyl- 1H- pyrrol-3 -yl)-3 - [(2-bromoacryloyl)amino] - 1 -methyl- 1 H-pyrazole-5-carboxamide;
7. N-(5-{[(5-{[(5-{[(2-{[amino(imino)methyl]amino}ethyl)amino]carbonyl}-l- methyl- 1 H-pyrrol-3 -yl)arnino] carbonyl} - 1 -methyl- 1 H-pyrrol-3 - yl)amino]carbonyl}-l-methyl-lH-pyrrol-3-yl)-4-[(2-chloroacryloyl)amino]-l- methyl- 1 H-pyrrole-2-carboxamide hydrochloride;
8. N-(5-{[(5-{[(3-{ [amino(imino)methyl] amino } propyl)amino] carbonyl} - 1 -methyl- 1 H-pyrrol-3-yl)amino]carbonyl} - 1 -methyl- 1 H-pyrrol-3-yl)-4-[(2- bromoacryloyl)amino]-l-methyl-lH-pyrrole-2-carboxamide hydrochloride;
9. N-(5-{[(5-{[(3-amino-3-iminopropyl)amino]carbonyl}-l-methyl-lH-pyrrol-3- yl)amino]carbonyl}-l-methyl-lH-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-l- methyl-lH-pyrrole-2-carboxamide hydrochloride; and
10. N- {5-[( {5-[( {5-[( {3-[(aminocarbonyl)amino]propyl} amino)carbonyl]- 1 -methyl- 1 H-pyrrol-3 -yl} amino)carbonyl] - 1 -methyl- 1 H-pyrrol-3 -yl} amino)carbonyl] - 1 - methyl- 1 H-pyrrol-3 -yl} -4- [(2-bromoacryloyl)amino] - 1 -methyl- 1 H-pyrrole-2- carboxamide.
10. Products comprising an acryloyl distamycin derivative of formula (I):
Figure imgf000015_0001
wherein:
Ri is a bromine or chlorine atom; R2 is a distamycin or distamycin-like framework; or a pharmaceutically acceptable salt thereof; an antimicrotubule agent and/or an antimetabolite, as a combined preparation for simultaneous, separate or sequential use in the treatment of tumors.
11. Products according to claim 10 wherein the antimicrotubule agent is selected from taxanes, including paclitaxel and docetaxel; vinca alkaloids, including vincristine, vinblastine, vindesine, vinorelbine; and estramustine, optionally encapsulated within liposomes.
12. Products according to claim 11 wherein the antimicrotubule agent is paclitaxel or estramustine.
13. Products according to claim 10 wherein the antimetabolite is selected from antifolates, including methotrexate, tomudex and trimetrexate; 5-fluoropyrimidine derivatives, including 5-fluorouracil, floxuridine, ftorafur and capecitabine; and cytidine analogs, including cytarabine, azacitidine and gemcitabine.
14. Products according to claim 13 wherein the antimetabolite is selected from 5- fluorouracil or gemcitabine.
15. Products according to claim 10 comprising an acryloyl distamycin derivative of formula (I)
Figure imgf000016_0001
wherein:
Ri is a bromine or chlorine atom;
R2 is a group of formula (U)
Figure imgf000016_0002
wherein m is an integer from 0 to 2; n is an integer from 2 to 5; r is O or 1;
X and Y are, the same or different and independently for each heterocycUc ring, a nitrogen atom or a CH group;
G is phenylene, a 5 or 6 membered saturated or unsaturated heterocycUc ring with from 1 to 3 heteroatoms selected among N, O or S, or it is a group of formula (HI) below:
Figure imgf000016_0003
wherein Q is a nitrogen atom or a CH group and W is an oxygen or sulfur atom or it is a group NR3 wherein R3 is hydrogen or Cι-C alkyl; B is selected from the group consisting of
Figure imgf000017_0001
— CN . ~NR5R6 . - - CONR5R6 — NHCONR 5-F 6 wherein R is cyano, amino, hydroxy or Cι-C4 alkoxy; R5, R6 and R7, the same or different, are hydrogen or Cι-C4 alkyl.
16. Products according to claim 10 wherein the acryloyl distamycin derivative is selected from the group as defined in claim 9.
17. Use of an acryloyl distamycin derivative of formula (I), as defined in claim 1 or in any one of claims from 6 to 9 in the preparation of a medicament for use in combination therapy with an antimicrotubule agent and/or an antimetabolite in the treatment of tumors.
18. Use according to claim 17 wherein the medicament further comprises the said antimicrotubule agent and/or antimetabolite.
19. Use according to claim 17 or 18 wherein the acryloyl distamycin derivative is selected from the group as defined in claim 9.
20. Use according to any one of claims 17 to 19 wherein the tumor is selected from breast, ovary, lung, colon, kidney, stomach, pancreas, liver, melanoma, leukemia and brain tumors.
21. Use of an acryloyl distamycin derivative of formula (I), as defined in claim 1 or in any one of claims form 6 to 9 in the preparation of a medicament for use in combination therapy with an antimicrotubule agent and/or an antimetabolite in the prevention or treatment of metastasis or in the treatment of tumors by inhibition of angiogenesis.
22. Use according to claim 21 wherein the medicament further comprises the said antimicrotubule agent and/or antimetabolite.
23. A method of treating a mammal, including humans, suffering from a neoplastic disease state, which method comprises administering to said mammal the acryloyl distamycin derivative of formula (I), as defined in claim 1 or any one of claims 6 to 9, an antimicrotubule agent and/or an antimetabolite, in amounts effective to produce a synergistic antineoplastic effect.
24. A method for lowering the side effects caused by antineoplastic therapy with an antineoplastic agent, in a mammal in need thereof including humans, the method comprising administering to said mammal a combined preparation comprising an antimicrotubule agent and/or an antimetabolite with an acryloyl distamycin derivative of formula (I), as defined in claim 1 or any one of claims from 6 to 7, in amounts effective to produce a synergistic antineoplastic effect.
25. A pharmaceutical composition according to claim 1 wherem the acryloyl distamycin derivative, optionally in the form of a pharmaceutically acceptable salt, is N-(5-{[(5-{[(5-{[(2-{[amino(imino)methyl]amino}ethyl)amino]carbonyl}-l-methyl- lH-pyrrol-3-yl)amino]carbonyl}-l-methyl-lH-pyrrol-3-yl)amino]carbonyl}-l-methyl- lH-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-l-methyl-lH-pyrrole-2-carboxamide, and the antimetabolite is gemcitabine.
PCT/EP2001/007060 2000-06-23 2001-06-20 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites Ceased WO2001097618A2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
EEP200200688A EE05359B1 (en) 2000-06-23 2001-06-20 A pharmaceutical composition comprising an acr listin derivative, an anti-microtubule agent, and / or an antimetabolite, the use of an acr listin derivative in the preparation of an anti-tumor drug, and a combined pharmaceutical formulation.
HU0301334A HUP0301334A3 (en) 2000-06-23 2001-06-20 Combined compositions against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolited
MXPA02012165A MXPA02012165A (en) 2000-06-23 2001-06-20 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites.
US10/297,620 US7642229B2 (en) 2000-06-23 2001-06-20 Pharmaceutical composition and a product which includes a substituted acryloyl distamycin derivative, an antimicrotubule agent and/or an antimetabolite
PL363696A PL200504B1 (en) 2000-06-23 2001-06-20 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
IL15317801A IL153178A0 (en) 2000-06-23 2001-06-20 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
DE60143681T DE60143681D1 (en) 2000-06-23 2001-06-20 Combination therapy against tumors with substituted acryloyl-distamycin derivatives, taxanes and / or antimetabolites
AU2001267553A AU2001267553B2 (en) 2000-06-23 2001-06-20 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
EP01945297A EP1299110B1 (en) 2000-06-23 2001-06-20 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and antimetabolites
JP2002503104A JP2003535874A (en) 2000-06-23 2001-06-20 Combination therapy for tumors containing substituted acryloyldistamycin derivatives, taxanes and / or antimetabolites
BR0111814-5A BR0111814A (en) 2000-06-23 2001-06-20 Pharmaceutical composition and products comprising substituted acrylamide distamycin derivatives, taxanes and / or antimetabolites for combined tumor therapy and their use
EA200300059A EA006709B1 (en) 2000-06-23 2001-06-20 Combined therapy against tumors comprising use of substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
AU6755301A AU6755301A (en) 2000-06-23 2001-06-20 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
NZ523001A NZ523001A (en) 2000-06-23 2001-06-20 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
DE60136706T DE60136706D1 (en) 2000-06-23 2001-06-20 YCIN-ACRYLOYL DERIVATIVES AND ANTIMETABOLIC AGENTS
HK03106774.6A HK1054506B (en) 2000-06-23 2001-06-20 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
SK1829-2002A SK287398B6 (en) 2000-06-23 2001-06-20 Pharmaceutical preparation comprising acryloyl distamycin derivative and gemcitabine
CA002412054A CA2412054A1 (en) 2000-06-23 2001-06-20 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
KR1020027017409A KR100861668B1 (en) 2000-06-23 2001-06-20 Antitumor combination therapeutics, including substituted acryloyl disamycin derivatives, taxanes and / or antimetabolic agents
IL153178A IL153178A (en) 2000-06-23 2002-11-28 Pharmaceutical compositions comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites and products comprising same for combined treatment of tumors
NO20026076A NO329967B1 (en) 2000-06-23 2002-12-18 Pharmaceutical preparation and products including acryloyl distamycin derivatives and antimetabolites, and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0015446.8 2000-06-23
GBGB0015446.8A GB0015446D0 (en) 2000-06-23 2000-06-23 Combined therapy against tumors comprising substituted acryloyl distamycin derivates,taxanes and/or antimetabolites

Publications (2)

Publication Number Publication Date
WO2001097618A2 true WO2001097618A2 (en) 2001-12-27
WO2001097618A3 WO2001097618A3 (en) 2002-06-13

Family

ID=9894287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007060 Ceased WO2001097618A2 (en) 2000-06-23 2001-06-20 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites

Country Status (25)

Country Link
US (1) US7642229B2 (en)
EP (2) EP1299110B1 (en)
JP (1) JP2003535874A (en)
KR (1) KR100861668B1 (en)
CN (1) CN100479824C (en)
AT (2) ATE491457T1 (en)
AU (2) AU2001267553B2 (en)
BR (1) BR0111814A (en)
CA (1) CA2412054A1 (en)
CZ (1) CZ20024107A3 (en)
DE (2) DE60143681D1 (en)
EA (1) EA006709B1 (en)
EE (1) EE05359B1 (en)
ES (1) ES2317913T3 (en)
GB (1) GB0015446D0 (en)
HK (1) HK1054506B (en)
HU (1) HUP0301334A3 (en)
IL (2) IL153178A0 (en)
MX (1) MXPA02012165A (en)
NO (1) NO329967B1 (en)
NZ (2) NZ543318A (en)
PL (1) PL200504B1 (en)
SK (1) SK287398B6 (en)
WO (1) WO2001097618A2 (en)
ZA (1) ZA200209835B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070249651A1 (en) * 2001-06-20 2007-10-25 Nerviano Medical Sciences S.R.I. Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase I and II inhibitors
MD36Z (en) * 2008-12-02 2010-01-31 Василе ЖОВМИР Method for differential treatment of noninvasive ductal carcinoma in situ of mammary gland
MD35Z (en) * 2008-12-02 2010-01-31 Василе ЖОВМИР Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland
MD23Z (en) * 2008-12-02 2010-01-31 Василе ЖОВМИР Method of differential treatment of noninvasive lobular mammary carcinoma in situ
MD24Z (en) * 2008-12-02 2010-01-31 Василе ЖОВМИР Method of differential treatment of noninvasive mammary carcinoma

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT387013B (en) 1985-07-16 1988-11-25 Erba Farmitalia METHOD FOR PRODUCING POLY-4-AMINOPYRROL -2-CARBOXAMIDO DERIVATIVES
GB8612218D0 (en) 1986-05-20 1986-06-25 Erba Farmitalia Site specific alkylating agents
ES2036553T3 (en) 1986-10-07 1993-06-01 Boehringer Mannheim Italia S.P.A. PHARMACEUTICAL COMPOSITIONS THAT HAVE ANTINEOPLASTIC ACTIVITY.
GB8906709D0 (en) 1989-03-23 1989-05-10 Creighton Andrew M Acryloyl substituted pyrrole derivatives
JP2919867B2 (en) 1989-09-27 1999-07-19 千寿製薬株式会社 Antitumor agent
CA2139638A1 (en) * 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
US5633274A (en) * 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
IT1272234B (en) 1994-05-02 1997-06-16 Consiglio Nazionale Ricerche GLUTATIONIC DERIVATIVES OF ANTHRACYCLINES AND PROCEDURE TO OBTAIN THEM.
GB9416005D0 (en) 1994-08-08 1994-09-28 Erba Carlo Spa Peptidic compounds analogous to distamycin a and process for their preparation
US5597830A (en) * 1994-12-20 1997-01-28 Warner-Lambert Company Combination chemotherapy
US5880097A (en) 1996-01-04 1999-03-09 Terrapin Techologies, Inc. Tethered prodrugs
EP0880499A1 (en) 1996-02-02 1998-12-02 PHARMACIA & UPJOHN S.p.A. Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
GB9610079D0 (en) 1996-05-14 1996-07-17 Pharmacia Spa Distamycin deriratives process for preparing them and their use as antitumor and antiviral agents
GB9615692D0 (en) * 1996-07-25 1996-09-04 Pharmacia Spa Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
GB9623522D0 (en) * 1996-11-11 1997-01-08 Pharmacia & Upjohn Spa Benzoheterocycle distamycin derivatives process for preparing them and their use as antitumour and antiviral agents
GB9727524D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
GB9806692D0 (en) 1998-03-27 1998-05-27 Pharmacia & Upjohn Spa Benzoheterocyclic distamycin derivatives, process for preparing them and their use as antitumour agents
GB9806689D0 (en) 1998-03-27 1998-05-27 Pharmacia & Upjohn Spa Acryloyl derivatives analogous to distamycin,process for preparing them,and their use as antitumour and antiviral agents
GB9816653D0 (en) 1998-07-30 1998-09-30 Pharmacia & Upjohn Spa Oxidised sulfurated distamycin derivatives process for preparing them and their use as antitumor agents
GB9816652D0 (en) 1998-07-30 1998-09-30 Pharmacia & Upjohn Spa Sulfurated distamycin derivatives process for preparing them and their use as antitumor agents
GB9928703D0 (en) 1999-12-03 2000-02-02 Pharmacia & Upjohn Spa Acryloyl peptidic derivatives,process for their preparation and their use as antitumour agents
GB0011059D0 (en) 2000-05-08 2000-06-28 Pharmacia & Upjohn Spa Use of substituted acryloyl distamycin derivatives in the treatment of tumours associated with high levels of glutathione
US6576612B1 (en) * 2000-10-02 2003-06-10 Pharmacia Italia S.P.A. Antitumor therapy comprising distamycin derivatives
US6887851B2 (en) * 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
RU2314807C2 (en) * 2002-04-02 2008-01-20 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Method for applying combined antitumor therapy including substituted acryloyl distacmycin derivatives usage and radiation therapy

Also Published As

Publication number Publication date
BR0111814A (en) 2003-05-27
EP1889624B1 (en) 2010-12-15
HK1054506B (en) 2010-06-11
IL153178A (en) 2010-11-30
ES2317913T3 (en) 2009-05-01
EA006709B1 (en) 2006-02-24
PL200504B1 (en) 2009-01-30
EE05359B1 (en) 2010-12-15
US7642229B2 (en) 2010-01-05
ATE415165T1 (en) 2008-12-15
GB0015446D0 (en) 2000-08-16
AU2001267553B2 (en) 2006-02-23
PL363696A1 (en) 2004-11-29
SK18292002A3 (en) 2003-07-01
EP1299110B1 (en) 2008-11-26
IL153178A0 (en) 2003-06-24
DE60136706D1 (en) 2009-01-08
HK1054506A1 (en) 2003-12-05
KR100861668B1 (en) 2008-10-07
EP1889624A3 (en) 2009-02-25
EA200300059A1 (en) 2003-04-24
NZ543318A (en) 2007-11-30
ZA200209835B (en) 2003-12-04
MXPA02012165A (en) 2003-04-25
JP2003535874A (en) 2003-12-02
NO20026076L (en) 2002-12-18
CN1437473A (en) 2003-08-20
HUP0301334A3 (en) 2005-05-30
CN100479824C (en) 2009-04-22
NO329967B1 (en) 2011-01-31
EP1889624A2 (en) 2008-02-20
NO20026076D0 (en) 2002-12-18
ATE491457T1 (en) 2011-01-15
CA2412054A1 (en) 2001-12-27
DE60143681D1 (en) 2011-01-27
WO2001097618A3 (en) 2002-06-13
HUP0301334A2 (en) 2003-08-28
EP1299110A2 (en) 2003-04-09
US20040092453A1 (en) 2004-05-13
NZ523001A (en) 2006-07-28
SK287398B6 (en) 2010-08-09
AU6755301A (en) 2002-01-02
KR20030014721A (en) 2003-02-19
EE200200688A (en) 2004-06-15
CZ20024107A3 (en) 2003-05-14

Similar Documents

Publication Publication Date Title
AU2002221622B2 (en) Antitumor therapy comprising distamycin derivatives
KR100853955B1 (en) Pharmaceutical composition comprising acryloyl distamycin derivative and topical isomerase I and II inhibitors
AU2001278463A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
US7642229B2 (en) Pharmaceutical composition and a product which includes a substituted acryloyl distamycin derivative, an antimicrotubule agent and/or an antimetabolite
CA2410160C (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents
AU2001267553A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
AU2001281867A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 153178

Country of ref document: IL

Ref document number: 2001267553

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200209835

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 523001

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2412054

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/012165

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV2002-4107

Country of ref document: CZ

Ref document number: 10297620

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2002 503104

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 18292002

Country of ref document: SK

Ref document number: 1020027017409

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018116078

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001945297

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 78/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 03003265

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 200300059

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020027017409

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001945297

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2002-4107

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 50522009

Country of ref document: SK

Kind code of ref document: A